Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE-TBM: High-Dose Rifampicin, Isoniazid, Linezolid, and Pyrazinamide for Tuberculous Meningitis
NCT05383742Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2023
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of rifampicin, isoniazid, linezolid and pyrazinamide in tuberculous meningitis (TBM) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Modified Rankin Scale at 48 weeks. Started Dec 2023; status: recruiting.
02
Drugs
rifampicinisoniazidlinezolidpyrazinamide
03
Conditions
tuberculous meningitis (TBM)
Beyond the preview
Go deeper on NCT05383742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383742.